Schoenfeld, Katrin ; Harwardt, Julia ; Kolmar, Harald (2024)
Better safe than sorry: dual targeting antibodies for cancer immunotherapy.
In: Biological Chemistry
doi: 10.1515/hsz-2023-0329
Artikel, Bibliographie
Dies ist die neueste Version dieses Eintrags.
Kurzbeschreibung (Abstract)
Antibody-based therapies are revolutionizing cancer treatment and experience a steady increase from preclinical and clinical pipelines to market share. While the clinical success of monoclonal antibodies is frequently limited by low response rates, treatment resistance and various other factors, multispecific antibodies open up new prospects by addressing tumor complexity as well as immune response actuation potently improving safety and efficacy. Novel antibody approaches involve simultaneous binding of two antigens on one cell implying increased specificity and reduced tumor escape for dual tumor-associated antigen targeting and enhanced and durable cytotoxic effects for dual immune cell-related antigen targeting. This article reviews antibody and cell-based therapeutics for oncology with intrinsic dual targeting of either tumor cells or immune cells. As revealed in various preclinical studies and clinical trials, dual targeting molecules are promising candidates constituting the next generation of antibody drugs for fighting cancer.
| Typ des Eintrags: | Artikel |
|---|---|
| Erschienen: | 2024 |
| Autor(en): | Schoenfeld, Katrin ; Harwardt, Julia ; Kolmar, Harald |
| Art des Eintrags: | Bibliographie |
| Titel: | Better safe than sorry: dual targeting antibodies for cancer immunotherapy |
| Sprache: | Englisch |
| Publikationsjahr: | 2024 |
| Ort: | Berlin [u.a.] |
| Verlag: | De Gruyter |
| Titel der Zeitschrift, Zeitung oder Schriftenreihe: | Biological Chemistry |
| Kollation: | 17 Seiten |
| DOI: | 10.1515/hsz-2023-0329 |
| Zugehörige Links: | |
| Kurzbeschreibung (Abstract): | Antibody-based therapies are revolutionizing cancer treatment and experience a steady increase from preclinical and clinical pipelines to market share. While the clinical success of monoclonal antibodies is frequently limited by low response rates, treatment resistance and various other factors, multispecific antibodies open up new prospects by addressing tumor complexity as well as immune response actuation potently improving safety and efficacy. Novel antibody approaches involve simultaneous binding of two antigens on one cell implying increased specificity and reduced tumor escape for dual tumor-associated antigen targeting and enhanced and durable cytotoxic effects for dual immune cell-related antigen targeting. This article reviews antibody and cell-based therapeutics for oncology with intrinsic dual targeting of either tumor cells or immune cells. As revealed in various preclinical studies and clinical trials, dual targeting molecules are promising candidates constituting the next generation of antibody drugs for fighting cancer. |
| Freie Schlagworte: | bispecific antibody, cancer immunotherapy, dual targeting, immune cell engager, multispecific antibody |
| Zusätzliche Informationen: | Ahead of Print (aop) Version |
| Sachgruppe der Dewey Dezimalklassifikatin (DDC): | 500 Naturwissenschaften und Mathematik > 540 Chemie 500 Naturwissenschaften und Mathematik > 570 Biowissenschaften, Biologie |
| Fachbereich(e)/-gebiet(e): | 07 Fachbereich Chemie 07 Fachbereich Chemie > Clemens-Schöpf-Institut > Fachgebiet Biochemie 07 Fachbereich Chemie > Clemens-Schöpf-Institut |
| Hinterlegungsdatum: | 03 Jul 2024 11:21 |
| Letzte Änderung: | 03 Jul 2024 11:21 |
| PPN: | |
| Export: | |
| Suche nach Titel in: | TUfind oder in Google |
Verfügbare Versionen dieses Eintrags
-
Better safe than sorry: dual targeting antibodies for cancer immunotherapy. (deposited 02 Jul 2024 12:25)
- Better safe than sorry: dual targeting antibodies for cancer immunotherapy. (deposited 03 Jul 2024 11:21) [Gegenwärtig angezeigt]
 |
Frage zum Eintrag |
Optionen (nur für Redakteure)
 |
Redaktionelle Details anzeigen |
Drucken
Impressum